Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 482

1.

Enhanced tumor targeting of cRGD peptide-conjugated albumin nanoparticles in the BxPC-3 cell line.

Yu X, Song Y, Di Y, He H, Fu D, Jin C.

Sci Rep. 2016 Aug 12;6:31539. doi: 10.1038/srep31539.

2.

Health services research of integrative oncology in palliative care of patients with advanced pancreatic cancer.

Axtner J, Steele M, Kröz M, Spahn G, Matthes H, Schad F.

BMC Cancer. 2016 Aug 2;16:579. doi: 10.1186/s12885-016-2594-5.

3.

Enhanced mitochondrial glutamine anaplerosis suppresses pancreatic cancer growth through autophagy inhibition.

Jeong SM, Hwang S, Park K, Yang S, Seong RH.

Sci Rep. 2016 Aug 1;6:30767. doi: 10.1038/srep30767.

4.

Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy.

Lamarca A, Rigby C, McNamara MG, Hubner RA, Valle JW.

World J Gastroenterol. 2016 Jul 14;22(26):6065-75. doi: 10.3748/wjg.v22.i26.6065.

5.

Clinical and prognostic significance of serum transforming growth factor-beta1 levels in patients with pancreatic ductal adenocarcinoma.

Zhao J, Liang Y, Yin Q, Liu S, Wang Q, Tang Y, Cao C.

Braz J Med Biol Res. 2016 Jul 25;49(8). pii: S0100-879X2016000800705. doi: 10.1590/1414-431X20165485.

6.

Functionalized milk-protein-coated magnetic nanoparticles for MRI-monitored targeted therapy of pancreatic cancer.

Huang J, Qian W, Wang L, Wu H, Zhou H, Wang AY, Chen H, Yang L, Mao H.

Int J Nanomedicine. 2016 Jul 7;11:3087-99. doi: 10.2147/IJN.S92722. eCollection 2016.

7.

Cellular and Molecular Mechanisms of 3,3'-Diindolylmethane in Gastrointestinal Cancer.

Kim SM.

Int J Mol Sci. 2016 Jul 19;17(7). pii: E1155. doi: 10.3390/ijms17071155. Review.

8.

Detection of circulating tumor cells in patients with esophagogastric or pancreatic adenocarcinoma using the CellSearch® system: An observational feasibility study.

Piegeler T, Winder T, Kern S, Pestalozzi B, Schneider PM, Beck-Schimmer B.

Oncol Lett. 2016 Aug;12(2):1513-1518. Epub 2016 Jun 30.

10.

Pancreatic Cancer from Molecular Pathways to Treatment Opinion.

Karanikas M, Esempidis A, Chasan ZT, Deftereou T, Antonopoulou M, Bozali F, Amarantidis K, Man YG.

J Cancer. 2016 Jun 25;7(10):1328-39. doi: 10.7150/jca.15419. eCollection 2016. Review.

11.

Pancreatic cancer from bench to bedside: molecular pathways and treatment options.

Kosmidis C, Sapalidis K, Kotidis E, Mixalopoulos N, Zarogoulidis P, Tsavlis D, Baka S, Man YG, Kanellos J.

Ann Transl Med. 2016 May;4(9):165. doi: 10.21037/atm.2016.05.11. Review.

12.

Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis.

Tao LY, Zhang LF, Xiu DR, Yuan CH, Ma ZL, Jiang B.

World J Surg Oncol. 2016 May 16;14:146. doi: 10.1186/s12957-016-0888-3.

13.

Knockdown of ZFR suppresses cell proliferation and invasion of human pancreatic cancer.

Zhao X, Chen M, Tan J.

Biol Res. 2016 May 13;49(1):26. doi: 10.1186/s40659-016-0086-3.

14.

Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.

Morimoto M, Matsuo Y, Koide S, Tsuboi K, Shamoto T, Sato T, Saito K, Takahashi H, Takeyama H.

BMC Cancer. 2016 May 12;16:305. doi: 10.1186/s12885-016-2340-z.

15.

Non-invasive biomarkers in pancreatic cancer diagnosis: what we need versus what we have.

Herreros-Villanueva M, Bujanda L.

Ann Transl Med. 2016 Apr;4(7):134. doi: 10.21037/atm.2016.03.44. Review.

16.

Serum Mac-2 binding protein is a novel biomarker for chronic pancreatitis.

Maekawa T, Kamada Y, Ebisutani Y, Ueda M, Hata T, Kawamoto K, Takamatsu S, Mizutani K, Shimomura M, Sobajima T, Fujii H, Nakayama K, Nishino K, Yamada M, Kumada T, Ito T, Eguchi H, Nagano H, Miyoshi E.

World J Gastroenterol. 2016 May 7;22(17):4403-10. doi: 10.3748/wjg.v22.i17.4403.

17.

Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?

Brunet LR, Hagemann T, Andrew G, Mudan S, Marabelle A.

Oncoimmunology. 2015 Dec 18;5(4):e1112942. eCollection 2016 Apr. Review.

18.

ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer.

Wilson JM, Fokas E, Dutton SJ, Patel N, Hawkins MA, Eccles C, Chu KY, Durrant L, Abraham AG, Partridge M, Woodward M, O'Neill E, Maughan T, McKenna WG, Mukherjee S, Brunner TB.

Radiother Oncol. 2016 May;119(2):306-11. doi: 10.1016/j.radonc.2016.03.021. Epub 2016 Apr 23.

19.

Age-based computer-aided diagnosis approach for pancreatic cancer on endoscopic ultrasound images.

Ozkan M, Cakiroglu M, Kocaman O, Kurt M, Yilmaz B, Can G, Korkmaz U, Dandil E, Eksi Z.

Endosc Ultrasound. 2016 Mar-Apr;5(2):101-7. doi: 10.4103/2303-9027.180473.

Items per page

Supplemental Content

Write to the Help Desk